malignant hyperthermia
TRANSCRIPT
DR. ABDUL AZIZ AL HAZAZIRESIDENT IN ANAESTHESIA AND CRITICAL CARE
SUPERVISED BY
DR. DJURBERG HANSSENIOR CONSULTANT ANAESTHETIST
MALIGNANT HYPERTHERMIA
2
Goals and Objectives
DefinitionIncidenceAetiologyClinical presentationTriggering and safe agentsManagement of MH crisisAnaesthesia for MH-susceptible patientsConclusion
3
Definition MH was first described by Dr Michael Denbo-rough in 1960. It is an acute hyper-metabolic state. Susceptible patients when exposed to a triggering agent. reduction in the reuptake of calcium by the sarcoplasmic reticulum
◦ Acidosis, ◦ Tachycardia◦ Hypercarbia◦ Qlycolisis ◦ Hypoxemia, ◦ Heat production (hyperthermia).
4
Incidence Incidence is about 1 in 10–15 000.
◦ 1: 40,000 in Adults◦ 1:15,000in Children
Previously mortality (70–80%). Young adults, especially males. Minor surgical procedures
5
Changes in Incidence Education ETCO2
Dantrolene
6
Aetiology Genetically related and inherited disease. Ryanodine receptor gene deficiency on chromosome 19
7
Clinical Presentation No one sign is unique to MH. The clinical signs:
◦ Muscle rigidity ◦ Hyperkalemia ◦ High CK◦ Myoglobinurea ◦ Tachycardia ◦ Increased CO2 ◦ Metabolic acidosis
An unexplained increase in ETCO2 and a concomitant tachycardia. (Important to exclude other more common causes) Masseter muscle spasm (early warning sign) Increase in temperature (late sign)
8
Signs of Fulminant MH Episode
9
Triggering AgentsInhalation Anaesthetic Agents Choroform (Trichloromethane, Methyltrichloride) Desflurane Enflurane Halothane Isoflurane Methoxyflurane Sevoflurane Trichloroethylene Xenon (Rarely Used)
Depolarizing Muscle Relaxants Succinylcholine (Suxamethonium)
10
Safe Agents
Barbiturates / Intravenous Anesthetics Diazepam Etomidate (Amidate) Hexobarbital Ketamine (Ketalar) Methohexital (Brevital) Midazolam Propofol (Diprivan) Thiopental (Pentothal)
Inhaled Non-Volatile General Anesthetic: Nitrous Oxide
11
Safe Agents
Local Anaesthetics: Amethocaine Articaine Bupivicaine Dibucaine Etidocaine Lidocaine (Xylocaine) Levobupivacaine Mepivicaine (Carbocaine) Procaine (Novocain) Prilocaine (Citanest) Ropivacaine
Narcotics (Opioids): Alfentanil (Alfenta) Codeine (Methyl
Morphine) Fentanyl (Sublimaze) Hydromorphone (Dilaudid) Meperidine (Demerol) Methadone Morphine Naloxone Oxycodone Remifentanil Sufentanil (Sufenta)
12
Safe Agents
Safe Muscle Relaxants: Arduan (Pipecuronium) Curare (The active ingredient is Tubocurraine) Gallamine Metocurine Mivacron (Mivacurium) Neuromax (Doxacurium) Nimbex (Cisatracurium) Norcuron (Vecuronium) Pavulon (Pancuronium) Tracrium (Atracurium) Zemuron (Rocuronium)
13
ABCs of Managing Malignant
Hyperthermia
A Ask about personal and family past history of MH or Adverse Anaesthesia reactions Be Aware of clinical signs of MH.
B Body temperature monitoring
C Capnographic monitoring
D Dantrolene
ABCs of Managing Malignant Hyperthermia
15
Intra-operativeA Awareness
Airway
B Breathing Body temperature high (late sign).
C Capnography Circulation: cardiac arrhythmias, tachy/bradycardia, hyper/hypotension.
D Drugs (succinylcholine, potent halogens)?
E Exposure/ Examine the patient: skin color, perfusion, temperature, urine color, extremities, muscle tone.
16
Emergency Treatment Ask for Help. Ask for the MH cart and for dantrolene. Stop anesthesia triggering agents and the surgery. Hyperventilate with 100% oxygen. Cooling, if the patient is hot: insert large intravenous bore
catheters. Call MH Hotline:
1-800-644-9737 or 1-315-464-7079 DANTROLENE: give dantrolene IV, 2.5 mg/kg, and repeat the dose
until the signs are controlled. Check Electrolytes, especially potassium.
17
Dantrolene for MH Crisis
20 mg/60 ml (sterile water) = 1 mg/3ml 70 kg patient:
2.5 mg/kg = 175 mg or 525 ml (9 vials)
~10 mg/kg = 700 mg or 2100 ml (35 vials)
18
Secondary TreatmentA Acidosis?
B Bicarbonate?
C Circulation/monitoring
D Dysrhythmias
E Electrolytes
19
Cont…F Follow up:
A: ABG
B: Body temperature (core)
C: CO2(end tidal), CK, Coagulation tests.
D: Diuresis
E: Electrolytes.
20
Anaesthesia for MH-susceptible patient
A Anesthesia machine preparation Anesthesia
B Body temperature monitoring.
C Capnography
D Dantrolene Discharge, if no problems, after 2.5 hours.
21
Timeline of patient injury Within minutes…
◦ Death from hyperkalemia induced arrhythmia Within hours…
◦Death from DIC and/or MOSF Within days…
◦Rhabdomyolysis induced Renal failure◦Cerebral edema / Coma
22
Conclusion
MH is a potentially lethal genetic disorder. Mortality rate is >70% without treatment (DANTROLENE) !!! With treatment mortality < 5% Pattern of clinical signs are consistent but individual signs are non-
diagnostic Need high index of suspicion when patients develop
hyperdynamic/hypermetabolic signs.
23